邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肥厚型心肌病心脏性猝死的高危因素及预防

潘玉惠,  桑文涛,  边圆,  徐峰

downloadPDF
文章导航 > 协和医学杂志  > 2023 > 优先出版
潘玉惠, 桑文涛, 边圆, 徐峰. 肥厚型心肌病心脏性猝死的高危因素及预防[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0627
引用本文: 潘玉惠, 桑文涛, 边圆, 徐峰. 肥厚型心肌病心脏性猝死的高危因素及预防[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0627
shu
PAN Yuhui, SANG Wentao, BIAN Yuan, XU Feng. Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0627
Citation: PAN Yuhui, SANG Wentao, BIAN Yuan, XU Feng. Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0627
shu

肥厚型心肌病心脏性猝死的高危因素及预防

doi: 10.12290/xhyxzz.2022-0627

  • 1 山东大学齐鲁医院急诊科&胸痛中心, 济南 250012;

  • 2 山东省急危重症医学临床研究中心, 济南 250012

基金项目: 

泰山学者攀登计划专家建设工程专项经费（tspd20181220）

山东省重点研发计划（2021ZLGX02）

国家重点研发计划（2020YFC1512700）

详细信息
    通讯作者:

    徐峰，E-mail：xufengsdu@126.com；边圆，E-mail：bianyuan@sdu.edu.cn

    徐峰，E-mail：xufengsdu@126.com；边圆，E-mail：bianyuan@sdu.edu.cn

  • 中图分类号: R459.7

Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention

  • 1 Department of Emergency Medicine, Chest Pain Center, Shandong Provincial Clinical Research, Jinan 250012, China;

  • 2 Center for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012, China

    摘要
  • 摘要: 肥厚型心肌病（hypertrophic Cardiomyopathy，HCM）是最常见的遗传性心肌病之一，心脏性猝死是其最严重的结局。及早识别、早期预防可推迟或避免心脏骤停的发生，因此，明确HCM的猝死高危因素对于患者预后至关重要。目前HCM公认的高危因素主要包括猝死家族史、非持续性室性心动过速、严重左心室肥厚、不明原因晕厥、左心室射血分数<50%的终末期肥厚型心肌病、任何大小的左心室心尖室壁瘤以及广泛晚期钆增强等，预防措施主要包括药物治疗、外科室间隔心肌切除术、室间隔心肌酒精消融术和植入式心脏复律除颤器等。本文围绕识别肥厚型心肌病引发心脏性猝死的高危因素以及预防策略，就HCM预防、诊断、治疗方面的最新研究进展作一综述，以期为改善HCM患者的临床结局提供指导。
    Abstract: Hypertrophic cardiomyopathy is one of the most common hereditary cardiomyopathy, the most serious outcome of which is sudden cardiac death（SCD） . Early recognition and prevention may delay or avoid the onset of cardiac arrest. Therefore, it is important to identify the high-risk factors of SCD in patients with hypertrophic cardiomyopathy and prevent cardiac arrest. At present, the recognized high risk factors mainly include family history of sudden death, unexplained syncope, non-sustained ventricular tachycardia, severe left ventricular hypertrophy, left ventricular dysfunction, left ventricular systolic dysfunction, etc. The main preventive measures involve medical treatment, surgical septal myectomy, alcohol septal ablation, and implantable cardiac defibrillator. This article mainly focuses on the identification of high-risk factors and prevention strategies of SCD caused by hypertrophic cardiomyopathy, and reviews the latest progress of prevention, diagnosis and treatment of hypertrophic cardiomyopathy, to provide guidance for prevention of SCD caused by hypertrophic cardiomyopathy.
    • HTML全文
    • 参考文献(47)
  • [1] 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 中华医学会心血管分会心力衰竭学组, 等. 中国肥厚型心肌病指南2022[J]. 中华心力衰竭和心肌病杂志,2022,06:80-105.
    [2] Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy[J]. Heart,2006,92:785-791.
    [3] Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods[J]. Circulation,1995,92:700-704.
    [4] Crocker TF, Brown L, Lam N, et al. Information provision for stroke survivors and their carers[J]. Cochrane Database Syst Rev,2021,11:CD001919.
    [5] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J,2014,35:2733-2779.
    [6] Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2020,142:e533-e557.
    [7] Wu G, Liu J, Wang S, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy[J].Heart,2021,107:1576-1583.
    [8] Bayonas-Ruiz A, Muñoz-Franco FM, Ferrer V, et al. Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis[J].J Clin Med,2021,10:2312.
    [9] Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J,2022,43:3997-4126.
    [10] Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update[J].JACC Heart Fail,2018,6:364-375.
    [11] Maron MS. Family History of Sudden Death Should Be a Primary Indication for Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy[J]. Can J Cardiol,2015,31:1402-1406.
    [12] Liu Q, Li D, Berger AE, et al. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis[J].Sci Rep,2017,7:11957.
    [13] Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy[J].Circulation,2009,119:1703-1710.
    [14] Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events[J].Pediatr cardiol,2011,32:1096-1105.
    [15] Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2003,41:315-321.
    [16] O'Mahony C, Jichi F, Monserrat L, et al. Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy[J].Circ Arrhythm Electrophysiol,2016,9:e003818.
    [17] Norrish G, Ding T, Field E, et al. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy[J].Circulation Arrhythm Electrophysiol,2022,15:e010075.
    [18] Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy[J].Circulation,2006,114:216-225.
    [19] Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction[J]. J Am Coll Cardiol,2020,75:3033-3043.
    [20] Rowin EJ, Maron BJ, Chokshi A, et al. Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age[J]. Pacing Clin Electrophysiol,2018,41:1031-1033.
    [21] Adamczak DM, Oko-Sarnowska Z. Sudden Cardiac Death in Hypertrophic Cardiomyopathy[J]. Cardiol Rev,2018,26:145-151.
    [22] Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management[J]. J Am Coll Cardiol,2017,69:761-773.
    [23] Kamp NJ, Chery G, Kosinski AS, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis[J]. Prog Cardiovasc Dis,2021,66:10-16.
    [24] Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis[J]. JACC Cardiovasc Imaging,2016,9:1392-1402.
    [25] Amano Y, Yanagisawa F, Kitamura M, et al.Relationship of Nonseptal Late Gadolinium Enhancement to Ventricular Tachyarrhythmia in Hypertrophic Cardiomyopathy[J]. J Comput Assist Tomogr,41:768-771.
    [26] Li X, Lai L, Luo R, et al. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study[J]. J Cardiovasc Transl Res,2021,14:1001-1016.
    [27] Aquaro GD, Grigoratos C, Bracco A, et al. Late Gadolinium Enhancement-Dispersion Mapping: A New Magnetic Resonance Imaging Technique to Assess Prognosis in Patients With Hypertrophic Cardiomyopathy and Low-Intermediate 5-Year Risk of Sudden Death[J]. Circ Cardiovasc Imaging,2020,13:e010489-e010489.
    [28] Shen H, Dong SY, Ren MS, et al. Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside[J]. Front Cardiovasc Med,2022,9:949294.
    [29] Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors[J].Heart rhythm,2012,9:57-63.
    [30] Sadoul N, Prasad K, Elliott PM, et al.Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy[J].Circulation,1997,96:2987-2991.
    [31] Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age[J]. Circulation,2013,127:585-593.
    [32] Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy[J]. Eur Heart J, 2006,27:1933-1941
    [33] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail,2016,18:891-975.
    [34] Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy[J].Eur Heart J,2013,34:2529-2537.
    [35] Sun XG, Hansen JE, Beshai JF, et al. Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure[J]. J Am Coll Cardiol,2010,55:1814-1823.
    [36] Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy[J]. Circ Heart Fail,2015,8:1022-1031.
    [37] Finocchiaro G, Haddad F, Knowles JW, et al. Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment[J].JACC Heart fail,2015,3:408-418.
    [38] Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin[J]. Xenobiotica,2019,49:718-733.
    [39] Anderson RL, Trivedi DV, Sarkar SS, et al. Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers[J]. Proc Natl Acad Sci U S A,2018,115:E8143-E8152.
    [40] Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet,2020,396:759-769.
    [41] Morrow AG, Lambrew CT, Braunwald E. IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. II. OPERATIVE TREATMENT AND THE RESULTS OF PRE- AND POSTOPERATIVE HEMODYNAMIC EVALUATIONS[J].Circulation,1964,30: 120-151.
    [42] Maron BJ, Rowin EJ, Casey SA, et al. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice[J].JAMA cardiol,2016,1:98-105.
    [43] Desai MY, Smedira NG, Dhillon A, et al. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria[J]. J Thorac Cardiovasc Surg,2018,156:750-759.
    [44] Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience[J]. Clin Res Cardiol,2008,97:234-243.
    [45] Bytyçi I, Nistri S, Mörner S, et al. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis[J].J Clin Med, 2020,9:3062.
    [46] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J].Eur Heart J,2021,42:373-498.
    [47] Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy[J].JAMA cardiol,2019,4:644-657.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  16
  • HTML全文浏览量:  2
  • PDF下载量:  4
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-10-31
  • 录用日期:  2023-02-07
  • 网络出版日期:  2023-02-23

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！